Antero Resources Corporation (AR) saw its value decrease by -1.29% as the stock dropped $-0.31 to finish the day at a closing price of $23.65. The stock was lighter in trading and has fluctuated between $19-$30.66 per share for the past year. The shares, which traded within a range of $23.6 to $24.14 during the day, are down by -12.24% in the past three months and down by -10.01% over the past six months. It is currently trading -6.09% below its 20 day moving average and -6.44% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $33.89 a share over the next twelve months. The current relative strength index (RSI) reading is 36.37.The technical indicator lead us to believe there will be no major movement any time soon, hold.
Antero Resources Corporation, an independent oil and natural gas company, acquires, explores, and develops natural gas, natural gas liquids, and oil properties in the United States. As of December 31, 2014, the company had 543,000 net acres of oil and gas properties located in the Appalachian Basin in West Virginia, Ohio, and Pennsylvania. It also owns and operates 153 miles of gas gathering pipelines in the Marcellus Shale; and 96 miles of low-pressure, high-pressure, and condensate pipelines in the Utica Shale. The company was formerly known as Antero Resources Appalachian Corporation and changed its name to Antero Resources Corporation in June 2013. Antero Resources Corporation was founded in 2002 and is headquartered in Denver, Colorado. Antero Resources Corporation operates as a subsidiary of Antero Resources Investment LLC.
Twilio Inc. (TWLO) shares were down in last trading by -1.43% to $28.85. It experienced lighter than average volume on day. The stock decreased in value by almost -9.02% over the past week and fell -14.95% in the past month. It is currently trading -14.26% below its 50 day moving average and -33.35% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -59.34% decrease in value from its one year high of $70.96. The RSI indicator value of 40.33, lead us to believe that it is a hold for now.
Twilio Inc. provides cloud communications platform that enables developers to build, scale, and operate communications within software applications through the cloud as a pay-as-you-go service in the United States and internationally. It offers programmable communications cloud software that enables developers to embed voice, messaging, video, and authentication capabilities into their applications through application programming interfaces. The company also provides use case products, such as a two-factor authentication solution. Twilio Inc. was founded in 2008 and is headquartered San Francisco, California.
Celgene Corporation (CELG) traded within a range of $115.12 to $117.55 after opening the day at $117.2. The company has seen its stock decrease in value by -3.35% so far this year. The stock was down close to -1.01% on light volume in last trading session and closed at $115.75 per share. After the recent fall, the stock is currently holding -8.86% below its 52 week high of $127 and 24.4% above its 12-month low of $93.05. The shares are up by over 10.73% in the last three months, and the RSI indicator value of 51.07 is neither bullish nor bearish, tempting investors to stay on the sidelines.
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID to treat multiple myeloma; and OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, ankylosing spondylitis, Behçet’s disease, atopic dermatitis, and ulcerative colitis. The company’s products also include VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); THALOMID for the patients with multiple myeloma and erythema nodosum leprosum; ISTODAX to treat cutaneous and peripheral T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN products. Its clinical stage products include OTEZLA for the treatment of various immune-inflammatory diseases; sotatercept for the treatment of renal anemia, beta-thalassemia and MDS; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; PDA-002 for the treat diabetic foot ulcers and peripheral neuropathy; and PNK-007 for hematological malignancies treatment. The company has collaborative agreements with Novartis Pharma AG; Acceleron Pharma; Agios Pharmaceuticals, Inc.; Epizyme Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; Acetylon Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; TriNetX, Inc.; Triphase Accelerator Corporation; Nurix Inc.; Abbott; Sage Bionetworks; and PharmAkea Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.